| Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress |
NORCROSS, Ga., May 12, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, presented a late-breaking oral presentation of the NAVIGATE study analysis at the EASL 2025 Congress, on May 10, 2025, in Amsterdam, Netherlands. The NAVIGATE study evaluated belapectin, a galectin-3 inhibitor, in patients with MASH cirrhosis and portal hypertension. |
globenewswire.com |
2025-05-12 12:00:00 |
Czytaj oryginał (ang.) |
| Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update |
NORCROSS, Ga., March 31, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2024. |
globenewswire.com |
2025-03-31 12:00:00 |
Czytaj oryginał (ang.) |
| Galectin Therapeutics to Present at the 2025 MASH-TAG Conference |
NORCROSS, Ga., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the top-line results of the NAVIGATE trial in patients with MASH cirrhosis and portal hypertension will be presented during the 2025 MASH-TAG Conference, being held January 9-11, 2025 in Park City, Utah. Additionally, Company's executive leadership will be hosting one-on-one meetings in San Franscico January 13-16, 2025, during JP Morgan Healthcare Conference and is looking forward to engaging external stakeholders on NAVIGATE topline results and discussing next steps for the belapectin program. |
globenewswire.com |
2025-01-10 10:00:00 |
Czytaj oryginał (ang.) |
| Why Is Small Cap Galectin Therapeutics Stock Trading Lower On Friday? |
On Friday, Galectin Therapeutics, Inc. GALT released results from its global Phase2/3 NAVIGATE trial evaluating belapectin in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis and portal hypertension. |
benzinga.com |
2024-12-20 12:29:33 |
Czytaj oryginał (ang.) |
| Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH |
NORCROSS, Ga., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced results from its global clinical trial NAVIGATE evaluating belapectin in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis and portal hypertension. |
globenewswire.com |
2024-12-20 10:00:00 |
Czytaj oryginał (ang.) |
| Here's Why Galectin Therapeutics (GALT) is Poised for a Turnaround After Losing -31.83% in 4 Weeks |
The heavy selling pressure might have exhausted for Galectin Therapeutics (GALT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
zacks.com |
2024-12-09 12:35:27 |
Czytaj oryginał (ang.) |
| Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting |
NORCROSS, Ga., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the presentation of three posters on the ongoing NAVIGATE trial in patients with MASH cirrhosis and portal hypertension at the American Association for the Study of Liver Diseases (AASLD)'s annual meeting 2024 Liver Meeting, being held November 15-19, 2024 in San Diego, California. |
globenewswire.com |
2024-11-18 10:00:00 |
Czytaj oryginał (ang.) |
| Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update |
NORCROSS, Ga., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended September 30, 2024. Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics, said “This past quarter, we remained laser-focus on advancing the NAVIGATE trial of belapectin in patients with MASH cirrhosis. As we eagerly await the topline results next month, we remain hopeful that belapectin may be a potential new treatment for the large number of patients in the U.S. with compensated cirrhosis, portal hypertension, and which have not developed esophageal varices. These patients represent a large unmet medical need.” |
globenewswire.com |
2024-11-14 10:00:00 |
Czytaj oryginał (ang.) |
| Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting |
NORCROSS, Ga., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that three abstracts from ongoing Phase 2b/3 adaptive, NAVIGATE trial in patients with MASH cirrhosis and portal hypertension have been accepted for poster presentation at the American Association for the Study of Liver Diseases (AASLD)'s annual meeting, 2024 Liver Meeting, being held November 15-19, 2024 in San Diego, California. |
globenewswire.com |
2024-10-15 12:00:00 |
Czytaj oryginał (ang.) |
| Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference |
NORCROSS, Ga., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that Joel Lewis, Chief Executive Officer and Khurram Jamil, M.D., Chief Medical Officer, will be attending the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York, NY. |
globenewswire.com |
2024-09-03 12:30:00 |
Czytaj oryginał (ang.) |
| Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update |
NORCROSS, Ga., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended June 30, 2024. |
globenewswire.com |
2024-08-13 12:00:00 |
Czytaj oryginał (ang.) |
| Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer |
NORCROSS, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D., an accomplished senior executive with expertise in liver disease to Chief Medical Officer effective immediately. |
globenewswire.com |
2024-08-01 12:00:00 |
Czytaj oryginał (ang.) |
| Meet the 10 biggest megadonors in the 2024 election cycle so far |
Following record-breaking fundraising by candidates in the 2022 midterms, this year's election cycle is shaping up to be another big one for megadonors. |
marketwatch.com |
2024-06-18 17:47:00 |
Czytaj oryginał (ang.) |
| Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress |
NORCROSS, Ga., June 04, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will attend the EASL 2024 meeting and deliver a scientific presentation. The meeting will be held June 5-8, 2024, in Milan, Italy. |
globenewswire.com |
2024-06-04 12:00:00 |
Czytaj oryginał (ang.) |
| Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update |
NORCROSS, Ga., May 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the quarter ended March 31, 2024. |
globenewswire.com |
2024-05-15 12:00:00 |
Czytaj oryginał (ang.) |
| GALT Stock Earnings: Galectin Therapeutics Meets EPS for Q4 2023 |
Galectin Therapeutics (NASDAQ: GALT ) just reported results for the fourth quarter of 2023. Galectin Therapeutics reported earnings per share of -16 cents. |
investorplace.com |
2024-04-05 12:52:57 |
Czytaj oryginał (ang.) |
| Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update |
NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31, 2023. |
globenewswire.com |
2024-03-29 10:00:00 |
Czytaj oryginał (ang.) |
| Galectin: Q4 2024 NASH Cirrhosis Data Readout Is A Major Inflection Point |
Interim results from the phase 2b/3 NAVIGATE study, using Belapectin for the prevention of esophageal varices in NASH Cirrhosis patients, expected Q4 of 2024. In a prior phase 2 study, it was shown that Belapectin was effective in treating patients who had not yet developed esophageal varices. Global non-alcoholic steatohepatitis market is expected to grow to $14.53 billion by 2028; 20% will develop NASH Cirrhosis and then about half will not have esophageal varices. |
seekingalpha.com |
2024-03-20 22:11:22 |
Czytaj oryginał (ang.) |
| Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development |
NORCROSS, Ga., March 12, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the appointment of Khurram Jamil, M.D. as Vice President, Clinical Development. Dr. Jamil brings to Galectin almost two decades of experience in clinical development across the biotechnology industry. |
globenewswire.com |
2024-03-12 10:00:00 |
Czytaj oryginał (ang.) |
| PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023 |
BOSTON--(BUSINESS WIRE)--PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023. |
businesswire.com |
2023-12-07 08:00:00 |
Czytaj oryginał (ang.) |
| UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update |
NORCROSS, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended September 30, 2023. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov . |
globenewswire.com |
2023-11-13 10:45:00 |
Czytaj oryginał (ang.) |
| Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update |
NORCROSS, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended September 30, 2023. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the U.S. Securities and Exchange Commission and is available at www.sec.gov . |
globenewswire.com |
2023-11-13 10:00:00 |
Czytaj oryginał (ang.) |
| Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD |
NORCROSS, Ga., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin-3, today announced that it will share five scientific presentations at The Liver Meeting™ 2023, hosted by the American Association for the Study of Liver Diseases (AASLD). The Liver Meeting™ will be held November 10-14, 2023, in Boston, Mass. |
globenewswire.com |
2023-11-03 10:00:00 |
Czytaj oryginał (ang.) |